Platelet Thrombi in Rejection Episodes
Biopsies of kidneys taken during rejection episodes have been shown to contain aggregates of platelets in the transplanted vessels (Porter 1967 ). These aggregates are not normally found at other times, except in those transplanted kidneys which show the effects of preformed antibody, and are rejected in the first few hours after transplantation. The recipients of kidneys showing this 'hyperacute rejection' may have demonstrable circulating antibody (Kissmeyer-Nielsen et al. 1966) . Such antibody may be formed as a result of sensitization by blood transfusion, pregnancy or a previous transplant. In the absence of such sensitization it takes some days after transplantation for the development of antibody, and rejection episodes are not found as early with first transplants as they are in patients with second grafts. It appears that the episodes are caused by the humoral antibody.
Since the demonstration that platelet aggregation in vitro could be initiated with immune complex (Movat et al. 1965 ) it has been possible to put forward a hypothesis to explain the rejection episode. This would suggest that antibody in the graft vessels, attached to transplantation antigens, would cause adherence of platelets with release of ADP which would aggregate normal platelets in the transplant vessels. When this aggregation was extensive it would be recognized clinically as a rejection episode. We have been able to show that the platelet count falls at the start of many rejection episodes, and that successful treatment of the episode is nearly always associated with a measurable rise in peripheral platelet count. When the patient's platelets were labelled with 51Cr and reinfused on the fourth day after transplantation, the labelled platelets disappeared from the blood at the start of the episode, and radioactivity, measured by external counting, accumulated in the kidney. These changes were both reversed by treatment with increased dosage of azathioprine and steroids. Both 6-mercaptopurine and hydrocortisone were shown to be able to prevent the release of ADP from platelets which had adhered to immune complex in vitro, but actinomycin. C, which has been used to treat rejection episodes in some centres, was found to be quite inactive.
[The work described in this paper has been published in preliminary form (Mowbray 1966 Patients treated with steroids and other immunosuppressive agents are particularly susceptible to infections. In many reports of renal transplanta-
